Testing a new implant for opioid use disorder
Treatments studied
Part of Mental health clinical trials.
This study tests a new implant (BICX104) with or without bupropion to see how safe it is and how it works in the body, compared to an existing treatment (Vivitrol). If you are healthy and not using opioids, you may be eligible to help researchers understand if this implant could be a new option for treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You are in good health as determined by a doctor (based on medical history, physical exam, and lab tests).
- You are not currently using opioids and have a negative urine drug test.
- Your body mass index (BMI) is between 18.5 and 30.
- You agree to use effective birth control if you could become pregnant.
- You have no history of seizures, certain heart conditions, or psychiatric disorders with suicidal thoughts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two forms of naltrexone (a medication used for alcohol and opioid dependence) in healthy volunteers. It tests how well the body processes and tolerates a low or high-dose implant versus the standard monthly injection.
This Phase 2 study tests whether a long-acting naltrexone implant can help people with opioid use disorder stay away from opioid relapse. You may get the implant after safely finishing opioid withdrawal and stopping other naltrexone dosing at the right time.
This trial tests a naltrexone implant designed to help people with moderate to severe alcohol use disorder cut down on drinking. The implant slowly releases medication for several months, so you don't have to remember to take a pill every day.
This trial tests whether a combination of buprenorphine (through your care plan) and a monthly extended-release naltrexone (XR-NTX) shot can help prevent opioid relapse. It may help people who are ready to move toward a naltrexone-based relapse-prevention treatment after detox.
This trial tests a long-acting, once-monthly injection of buprenorphine (BRIXADI) given from a mobile pharmacy clinic. It aims to see if this approach is acceptable and practical for people with opioid use disorder, making treatment more accessible.
This early-stage study looks at how opioids affect your experience of social situations and your brain activity. It may help researchers understand how opioid medicines influence social perception and brain signaling.
Hear when a new Healthy Adult Male and Female Volunteers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.